Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)

Haematologica. 2018 Oct;103(10):e473-e479. doi: 10.3324/haematol.2018.189969. Epub 2018 Apr 19.

Johannes M Waldschmidt^{1

2}, Alexander Keller^{1

2}, Gabriele Ihorst³, Olga Grishina³, Stefan Müller¹, Dagmar Wider¹, Anna V Frey⁴, Kristina King⁵, Roman Simon⁵, Annette May⁴, Pierfrancesco Tassone⁶, Justus Duyster^{1

2}, Manfred Jung⁵, Noopur Raje⁷, Ralph Wäsch^{1

2}, Monika Engelhardt^{8

2}

¹ Department of Haematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, Germany.
² Comprehensive Cancer Center Freiburg (CCCF), Faculty of Medicine, University of Freiburg, Germany.
³ Clinical Trials Unit, Faculty of Medicine, University of Freiburg, Germany.
⁴ Institute of Pathology, Faculty of Medicine, University of Freiburg, Germany.
⁵ Institute of Pharmaceutical Sciences, Faculty of Medicine, University of Freiburg, Germany.
⁶ Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy.
⁷ Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
⁸ Department of Haematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, Germany monika.engelhardt@uniklinik-freiburg.de.

No abstract available

Publication types